Worth reading
38Recurring
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
60.1
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2024年4月1日〜2024年6月30日ConsolidatedJapanese GAAPNet Sales13,608¥ millionYear on year +0.1%
Operating profit1,167¥ millionYear on year +60.1%
Ordinary income1,434¥ millionYear on year +52.3%
Net income attributable to owners of the parent968¥ millionYear on year +49.9%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets85,417¥ million
of which net assets 59,081 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueFunctional Materials Business ¥7,321 million (YoY +4.9%), Electronic materials and chemicals business ¥6,014 million (YoY -4.7%)
Segment profitFunctional Materials Business ¥533 million, Electronic materials and chemicals business ¥563 million
Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
Remarks2024年5月10日公表予想を据え置き
Revision to Earnings ForecastNot disclosed → Not disclosed
Factors Behind Changes in Business Performance
化粧品向け機能性微粒子製品の販売が好調であったとともに、導電性高分子薬剤の販売が伸長したこと等
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥56 million
Depreciation and amortization¥648 million
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2024年6月30日 |
| Net Sales | ¥13,608 million (YoY +0.1%) |
| Operating profit | ¥1,167 million (YoY +60.1%) |
| Ordinary income | ¥1,434 million (YoY +52.3%) |
| Profit attributable to owners of the parent | ¥968 million (YoY +49.9%) |
| Total assets | ¥85,417 million |
| Net assets | ¥59,081 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks 2024年5月10日公表予想を据え置き |
| Revision to Earnings Forecast | Not disclosed → Not disclosed |
| Segment revenue | Functional Materials Business ¥7,321 million (YoY +4.9%), Electronic materials and chemicals business ¥6,014 million (YoY -4.7%) |
| Segment profit | Functional Materials Business ¥533 million, Electronic materials and chemicals business ¥563 million |
| Depreciation and amortization | ¥648 million |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥56 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Factors Behind Changes in Business Performance | 化粧品向け機能性微粒子製品の販売が好調であったとともに、導電性高分子薬剤の販売が伸長したこと等 |
Items this document does not state (18)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品向け機能性微粒子製品の販売が好調で、導電性高分子薬剤の販売も伸長しました。通期予想の据え置きについては、原燃料価格の推移や地政学リスクの影響などにより先行きが不透明であることを理由としています。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.